title: Treatment of mitochondrial disorders: antioxidants and beyond.
abstract: Although mitochondrial disorders are among the most common inherited conditions that cause neurologic impairment, there are currently no U.S. Food and Drug Administration (FDA)-approved medications designed to treat primary mitochondrial disease. This is in part related to the lack of biomarkers to monitor disease status or response to treatment and the paucity of randomized, controlled clinical trials focused on mitochondrial disease therapies. Despite this discouraging historical precedent, a number of new approaches to mitochondrial disease therapy are on the horizon. By studying metabolites central to redox chemistry, investigators are gaining new insights into potential noninvasive biomarkers. Controlled clinical trials designed to study the effects of novel redox-modulating therapies, such as EPI-743, in patients with inherited mitochondrial disease are also underway. Furthermore, several new compounds with potential effects on inner mitochondrial membrane function and mitochondrial biogenesis are in development. Such advances are providing the foundation for a new era in mitochondrial disease therapeutics.
authors.affiliation: Department of Pediatrics, Division of Medical Genetics, Stanford University and the Lucile Packard Children's Hospital, Stanford, CA, USA greg.enns@stanford.edu.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Enns
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D006801:Humans; D028361:Mitochondrial Diseases / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic
chemical_list: D000975:Antioxidants
keywords: Bendavia; coenzyme q10; epi-743; epicatechin; mitochondrial disease; therapies; vitamins